In our current study, we have successfully validated that the sorafenib-treated groups exhibited a reduction in phosphorylated MEK, a critical downstream protein of RAF in tumors, thereby confirming the inhibition of pivotal tumor survival RAF/MEK/ERK signaling pathway. This evidence concerns the gene MAP2K7 and neoplasm.